UnitedHealth Drops Descovy as Generic Shakes Up PrEP Class

UnitedHealthcare is dropping coverage in its commercial plan formularies for Gilead Sciences, Inc.’s HIV pre-exposure prophylaxis (PrEP) medication Descovy (emtricitabine and tenofovir alafenamide), steering patients instead to Gilead’s Truvada (emtricitabine/tenofovir disoproxil fumarate) as a generic version of Truvada is set to launch.

Other plans are likely to follow suit in their PrEP formularies when Teva Pharmaceutical Industries Ltd. releases its generic version of Truvada on Sept. 30, one industry insider says. But formularies could be shaken up again in 2021 as an “A” rating from the U.S. Preventive Services Task Force (USPSTF) for PrEP takes effect, requiring plans to provide health plan members at high risk of HIV with access to PrEP without copayments or deductibles.

© 2023 MMIT
Freelance Reporter

Freelance Reporter Freelance Reporter

Related Posts

bills-and-pills
January 26

Medicare Enrollees May Still Face Affordability Issues After Part D Benefit Redesign

READ MORE
pills-in-hand
January 26

ICER Report Aims to Nudge Payers Toward Fairer Drug Coverage Policies

READ MORE
businessman-viewing-news-update-journalism-headline-on-a-laptop
January 26

News Briefs: Lilly Alzheimer’s Drug Fails to Win Accelerated Approval

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today